HALO logo

HALO
Halozyme Therapeutics Inc.

4,940
Mkt Cap
$8.41B
Volume
4,082.00
52W High
$82.22
52W Low
$47.50
PE Ratio
25.51
HALO Fundamentals
Price
$70.80
Prev Close
$70.93
Open
$71.94
50D MA
$65.59
Beta
0.73
Avg. Volume
1.39M
EPS (Annual)
$2.56
P/B
38.28
Rev/Employee
$3.3M
$10,373.12
Loading...
Loading...
News
all
press releases
Company News for May 13, 2026
Companies In The News Are: SPG, HIMS, NOVT, HALO.
Zacks·4h ago
News Placeholder
More News
News Placeholder
Halozyme's Q1 Earnings & Revenues Beat Estimates, Stock Up
HALO beats Q1 earnings estimates as royalty revenues from partner drugs and strong product sales lift revenues by 42% year over year.
Zacks·22h ago
News Placeholder
Halozyme Therapeutics (HALO) Reports Q1 Earnings: What Key Metrics Have to Say
While the top- and bottom-line numbers for Halozyme Therapeutics (HALO) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Zacks·2d ago
News Placeholder
Halozyme Therapeutics (HALO) Surpasses Q1 Earnings and Revenue Estimates
Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of +3.73% and +5.31%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2d ago
News Placeholder
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE
HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE HALOZYME REPORTS FIRST QUARTER 2026 RESULTS AND REITERATES 2026 FINANCIAL GUIDANCE PR Newswire SAN DIEGO, May 11, 2026 Announcing New $1 billion Share Repurchase ProgramProjecting to Buy Back at Least $400 million in...
PR Newswire·2d ago
News Placeholder
ANI Pharmaceuticals (ANIP) Tops Q1 Earnings and Revenue Estimates
ANI (ANIP) delivered earnings and revenue surprises of +60.16% and +15.61%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·5d ago
News Placeholder
ImmunityBio (IBRX) Reports Q1 Loss, Tops Revenue Estimates
ImmunityBio (IBRX) delivered earnings and revenue surprises of -12.50% and +7.56%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks·6d ago
News Placeholder
Halozyme Therapeutics (HALO) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Besides Wall Street's top-and-bottom-line estimates for Halozyme Therapeutics (HALO), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended March 2026.
Zacks·7d ago
News Placeholder
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon Technology
Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop ORKA-001 with Hypercon Technology Halozyme and Oruka Announce Global Collaboration and License Agreement to Develop...
PR Newswire·7d ago
News Placeholder
Halozyme Therapeutics AGM: Shareholders Elect Directors as CEO Torley Raises 2026 Guidance
Halozyme Therapeutics (NASDAQ:HALO) stockholders elected two Class I directors and approved several governance items at the company's annual meeting, while President and CEO Helen Torley highlighted 2025 execution, recent acquisitions, new commercial agreements, and updated financial guidance. Stoc...
MarketBeat·8d ago
<
1
2
...
>

Latest HALO News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.